Alx Oncology Holdings (ALXO) Revenue (2019 - 2020)

Alx Oncology Holdings (ALXO) reported Revenue of $527000.0 for Q2 2020, down 59.31% on a YoY basis from $1.3 million in Q3 2019, and down 19.54% sequentially from $655000.0 in Q1 2020.

Alx Oncology Holdings (ALXO) Revenue (2019 - 2020) Analysis & Trends

Alx Oncology Holdings (ALXO) has 2 years of Revenue data on file, last reported at $527000.0 in Q2 2020.

  • For the quarter ending Q2 2020, Revenue fell 59.31% year-over-year to $527000.0; the trailing twelve-month figure through Mar 2021 stood at $527000.0 (down 88.07% YoY), and the FY2020 full-year result was $1.2 million, down 75.35% from the prior year.
  • Revenue slipped to $527000.0 in Q2 2020, from $655000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $1.3 million in Q2 2019 to a low of $527000.0 in Q2 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 1.51 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 2.99 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 3.61 Bn
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 1.30 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Alx Oncology Holdings 213.33 Mn 213.33 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2020 527,000.00
Mar 31, 2020 655,000.00
Dec 31, 2019 1.21 Mn
Sep 30, 2019 1.26 Mn
Jun 30, 2019 1.30 Mn